Cellares and City of Hope announced a collaboration to evaluate automated manufacturing of City of Hope’s investigational gene-modified CAR T-cell therapy targeting glioblastoma multiforme, an aggressive solid tumor brain cancer with limited treatment options.
Researchers from City of Hope have developed a “plug-and-play” technology that adds engineered molecules to chimeric antigen receptor T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. The preclinical study offers a more flexible way to help CAR T cells keep pace with mutating tumors.
